Get started
Author

Alexandre Larivée

Observed names: Alexandre Larivee, Alexandre Larivée, Larivee, A., Larivée, Alexandre
ORCID: 0009-0009-1470-5128
Observed ORCID: 0009-0009-1470-5128
OpenAlex ID: A5031235167
Palladium-Catalyzed Direct C−H Arylation of N-Iminopyridinium Ylides: Application to the Synthesis of (±)-Anabasine
2007 · Alexandre Larivée, James J. Mousseau, et al. · Journal of the American Chemical Society · 200
Electrolytic Macrocyclizations: Scalable Synthesis of a Diazonamide‐Based Drug Development Candidate
2015 · Hui Ding, Patrick L. DeRoy, et al. · Angewandte Chemie International Edition · 138
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2023 · Andreas Varkaris, Ermira Pazolli, et al. · Cancer Discovery · 117
PDF
Palladium-Catalyzed Benzylic C−H Insertion of 2-Substituted N-Iminopyridinium Ylides
2008 · James J. Mousseau, Alexandre Larivée, et al. · Organic Letters · 115
The Leiodolide B Puzzle
2010 · Alexandre Larivée, John B. Unger, et al. · Angewandte Chemie International Edition · 81
Enantioselective Addition ofa Trifluoromethyl Anion to Aryl Ketones and Aldehydes
2003 · Stéphane Caron, Nga Do, et al. · Synthesis · 72
Electrolytic Macrocyclizations: Scalable Synthesis of a Diazonamide‐Based Drug Development Candidate
2015 · Hui Ding, Patrick L. DeRoy, et al. · Angewandte Chemie · 49
The Leiodolide B Puzzle
2010 · Alexandre Larivée, John B. Unger, et al. · Angewandte Chemie · 33
New Methodology Toward Chiral, Non-Racemic 2,5-cis-Substituted Piperidines via Suzuki Cross-Coupling
2006 · Alexandre Larivée, André B. Charette · Organic Letters · 26
Preparation of 3-O-aryl chloramphenicol derivatives via chemoselective copper-catalyzed O-arylation of (1R,2R)-(−)-N-BOC-2-amino-1-(4-nitrophenyl)-1,3-propanediol using triarylbismuthines
2016 · Tabinda Ahmad, Julien Dansereau, et al. · Tetrahedron Letters · 17
Identification of BRaf-Sparing Amino-Thienopyrimidines with Potent IRE1α Inhibitory Activity
2020 · Ramsay E. Beveridge, Heidi Ackerly Wallweber, et al. · ACS Medicinal Chemistry Letters · 11
Highly Regioselective Intermolecular Arylation of 1,2,3,4-Tetrahydropyridines
2008 · Guillaume Pelletier, Alexandre Larivée, et al. · Organic Letters · 9
Abstract P251: Discovery and characterization of RLY-2608: The first allosteric, mutant, and isoform-selective inhibitor of PI3Kα
2021 · Ermira Pazolli, Randy Kipp, et al. · Molecular Cancer Therapeutics · 5
Development of Heteroaromatic Silicon Fluoride Acceptors (HetSiFAs) for 18F-Labeled Radiopharmaceuticals
2025 · Thomas A. Singleton, HyunJune Jun, et al. · Journal of Medicinal Chemistry · 3
Abstract P5-16-10: RLY-2608: The first allosteric mutant- and isoform-selective inhibitor of PI3Kα, is efficacious as a single agent and drives regressions in combination with standard of care therapies in PIK3CA mutant breast cancer models
2022 · Ermira Pazolli, Randy Kipp, et al. · Cancer Research · 3
Table S2 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024 · Andreas Varkaris, Ermira Pazolli, et al.
Figure S1 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024 · Andreas Varkaris, Ermira Pazolli, et al.
Figure S2 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024 · Andreas Varkaris, Ermira Pazolli, et al.
Figure S7 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024 · Andreas Varkaris, Ermira Pazolli, et al.
Figure S7 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024 · Andreas Varkaris, Ermira Pazolli, et al.
Data from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024 · Andreas Varkaris, Ermira Pazolli, et al.
Figure S3 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024 · Andreas Varkaris, Ermira Pazolli, et al.
Figure S4 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024 · Andreas Varkaris, Ermira Pazolli, et al.
Supplemental Text from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024 · Andreas Varkaris, Ermira Pazolli, et al.
Table S1 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024 · Andreas Varkaris, Ermira Pazolli, et al.
Works count: 54
Citation count: 879
H-index: 11
I10-index: 11
Year
Topic
Type